Beyond Air (XAIR) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
30 Oct, 2026Executive summary
Annual meeting set for Dec. 10, 2026; agenda covers five director elections, auditor ratification, an advisory executive-pay vote, and conditional adjournment authority.
Fiscal year-end changed from March 31 to Dec. 31; April 1–Dec. 31, 2026 is a transition period, with the next fiscal year beginning Jan. 1, 2027.
Record date Oct. 12, 2026, with 1,665,482 common shares outstanding and one vote per share.
Voting matters and shareholder proposals
Board recommends FOR all five director nominees and FOR each of the three other proposals.
Directors are elected by plurality; auditor ratification, say-on-pay, and adjournment each require a majority of shares present and entitled to vote, subject to proposal-specific broker non-vote treatment.
Adjournment authority would permit additional proxy solicitation if quorum is lacking or more votes are needed; notice is required if an adjournment exceeds 30 days.
Rule 14a-8 proposals for the next annual meeting must arrive by July 2, 2027; other proposals are due Aug. 12–Sept. 11, 2027, subject to meeting-date exceptions.
Board of directors and corporate governance
Five director nominees; four directors are independent under Nasdaq standards. Board recommends election of Robert S. Goodman, Robert F. Carey, Dr. William Forbes, Yoori Lee, and Erick J. Lucera.
Board held seven meetings in FY ended March 31, 2026; each director attended at least 75% of applicable board and committee meetings.
Standing committees are audit, compensation, and nominating; each has three members, and committee meetings numbered five, two, and two, respectively, in FY ended March 31, 2026.
Robert F. Carey chairs the board and Robert S. Goodman leads day-to-day operations as CEO; the board will reassess this structure.
Latest events from Beyond Air
- Record LungFit PH revenue lifts guidance, but funding needs and FDA timing remain risks.XAIR
Q2 2027 - Five director nominees and three other proposals are on the Dec. 10, 2026 ballot.XAIR
Proxy filing - Four proposals face stockholders amid a fiscal-year transition and new CEO pay terms.XAIR
Proxy filing - Tankless nitric oxide therapy platform drives rapid growth and global market expansion.XAIR
Corporate presentation - Generation 2 device approval is set to unlock a $400M+ market with immediate deployment planned.XAIR
12th Annual Cantor Fitzgerald Global Healthcare Conference - Up to 5.4M shares registered for resale after a $10.2M private placement; focus on LungFit® growth.XAIR
Registration filing - Flat revenue, improved margins, and strong outlook depend on FDA approval and new product launch.XAIR
Q1 2027 - Revenue up 107% to $7.7M; Gen 2 launch and approval expected to drive major growth in 2027.XAIR
Q4 2026 - Next-generation system and global partnerships position the company for accelerated growth by 2027.XAIR
Piper Sandler 36th Annual Healthcare Conference